Cargando…

Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK

Anaplastic large cell lymphomas (ALCL) are mainly characterized by harboring the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). The ALK inhibitor, crizotinib specifically induced apoptosis in Ba/F3 cells expressing NPM-ALK by inhibiting the activation of NPM-ALK and its downstrea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uchihara, Yuki, Ueda, Fumihito, Tago, Kenji, Nakazawa, Yosuke, Ohe, Tomoyuki, Mashino, Tadahiko, Yokota, Shigenobu, Kasahara, Tadashi, Tamura, Hiroomi, Funakoshi-Tago, Megumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555621/ https://www.ncbi.nlm.nih.gov/pubmed/28806414 http://dx.doi.org/10.1371/journal.pone.0183003

Ejemplares similares

EBP2, a novel NPM‐ALK‐interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53
por: Uchihara, Yuki, et al.
Publicado: (2020)

A proline-type fullerene derivative inhibits adipogenesis by preventing PPARγ activation
por: Funakoshi-Tago, Megumi, et al.
Publicado: (2016)

Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells
por: Sumi, Kazuya, et al.
Publicado: (2022)

Coffee extract inhibits adipogenesis in 3T3-L1 preadipocyes by interrupting insulin signaling through the downregulation of IRS1
por: Maki, Chihiro, et al.
Publicado: (2017)

Coffee decoction enhances tamoxifen proapoptotic activity on MCF-7 cells
por: Funakoshi-Tago, Megumi, et al.
Publicado: (2020)

Critical Roles of Myc-ODC Axis in the Cellular Transformation Induced by Myeloproliferative Neoplasm-Associated JAK2 V617F Mutant
por: Funakoshi-Tago, Megumi, et al.
Publicado: (2013)

Oral consumption of α-glucosyl-hesperidin could prevent lens hardening, which causes presbyopia
por: Nakazawa, Yosuke, et al.
Publicado: (2020)

Hesperetin treatment attenuates glycation of lens proteins and advanced‑glycation end products generation
por: Doki, Yuri, et al.
Publicado: (2023)

Oral intake of α-glucosyl-hesperidin ameliorates selenite-induced cataract formation
por: Nakazawa, Yosuke, et al.
Publicado: (2020)

Effect of Alpha-Glucosyl-Hesperidin Consumption on Lens Sclerosis and Presbyopia
por: Nakazawa, Yosuke, et al.
Publicado: (2021)

Kampo medicines, Rokumigan, Hachimijiogan, and Goshajinkigan, significantly inhibit glucagon-induced CREB activation
por: Funakoshi-Tago, Megumi, et al.
Publicado: (2020)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Pyrocatechol, a component of coffee, suppresses LPS-induced inflammatory responses by inhibiting NF-κB and activating Nrf2
por: Funakoshi-Tago, Megumi, et al.
Publicado: (2020)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

Data supporting mitochondrial morphological changes by SPG13-associated HSPD1 mutants
por: Miyamoto, Yuki, et al.
Publicado: (2016)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
por: McDuff, Fiona Kate Elizabeth, et al.
Publicado: (2011)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Preparation and antioxidant/pro-oxidant activities of 3-monosubstituted 5-hydroxyoxindole derivatives
por: Yasuda, Daisuke, et al.
Publicado: (2016)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
por: Hida, Toyoaki, et al.
Publicado: (2016)

ST2 gene products critically contribute to cellular transformation caused by an oncogenic Ras mutant
por: Tago, Kenji, et al.
Publicado: (2017)

Synthesis and antitumor activity of novel pyridinium fullerene derivatives
por: Yasuno, Takumi, et al.
Publicado: (2019)

Development of Novel Diclofenac Analogs Designed to Avoid Metabolic Activation and Hepatocyte Toxicity
por: Tateishi, Yasuhiro, et al.
Publicado: (2020)

Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
por: Katagishi, Daiki, et al.
Publicado: (2023)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
por: Kreutmair, Stefanie, et al.
Publicado: (2022)

Data on the effect of hypomyelinating leukodystrophy 6 (HLD6)-associated mutations on the TUBB4A properties
por: Miyamoto, Yuki, et al.
Publicado: (2017)

STAT3 and ERK pathways are involved in cell growth stimulation of the ST2/IL1RL1 promoter
por: Tago, Kenji, et al.
Publicado: (2017)

ALK-driven tumors and targeted therapy: focus on crizotinib
por: Murga-Zamalloa, Carlos, et al.
Publicado: (2014)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells
por: Sorrentino, Domenico, et al.
Publicado: (2020)

A pyridinium-type fullerene derivative suppresses primary effusion lymphoma cell viability via the downregulation of the Wnt signaling pathway through the destabilization of β-catenin
por: Kadota, Ayano, et al.
Publicado: (2022)

SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein()
por: Vishwamitra, Deeksha, et al.
Publicado: (2015)

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
por: Lobello, Cosimo, et al.
Publicado: (2018)

TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK (+) T‐cell lymphoma
por: Shi, Wenyu, et al.
Publicado: (2017)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023)

Inhibition of Rac controls NPM–ALK-dependent lymphoma development and dissemination
por: Colomba, A, et al.
Publicado: (2011)

NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
por: Andraos, Elissa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_anhudlnrdmlgqp715nj7pnuh3v